Stock CP60 THE COOPER COMPANIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials The Cooper Companies, Inc. Börse Stuttgart

Equities

CP60

US2166485019

Medical Equipment, Supplies & Distribution

Real-time Estimate Tradegate
Other stock markets
 08:37:36 26/06/2024 BST 		5-day change 1st Jan Change
83.5 EUR +1.89% Intraday chart for The Cooper Companies, Inc. -3.36% -4.99%
06-06 Transcript : The Cooper Companies, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 01:30 PM
06-05 Transcript : The Cooper Companies, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 10:00 AM

Valuation

Fiscal Period: Oktober 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,426 15,646 20,556 13,491 15,439 17,763 - -
Enterprise Value (EV) 1 16,163 17,324 21,939 16,116 17,889 20,040 19,525 18,967
P/E ratio 31.2 x 66.3 x 7.05 x 35.2 x 52.7 x 41 x 29.1 x 25.1 x
Yield 0.02% 0.02% 0.01% 0.02% 0.02% 0.07% 0.07% -
Capitalization / Revenue 5.44 x 6.44 x 7.03 x 4.08 x 4.3 x 4.57 x 4.28 x 4.02 x
EV / Revenue 6.09 x 7.13 x 7.51 x 4.87 x 4.98 x 5.16 x 4.71 x 4.3 x
EV / EBITDA 18.2 x 24.1 x 23.6 x 17 x 14.7 x 17.4 x 15.5 x 13.9 x
EV / FCF 38.4 x 98.3 x 41.9 x 35.8 x 83.2 x 61.9 x 32.6 x 26.1 x
FCF Yield 2.61% 1.02% 2.39% 2.79% 1.2% 1.62% 3.07% 3.83%
Price to Book 4.01 x 4.14 x 2.99 x 1.89 x 2.04 x 2.22 x 2.09 x 1.96 x
Nbr of stocks (in thousands) 198,294 196,162 197,216 197,384 198,097 199,120 - -
Reference price 2 72.75 79.76 104.2 68.35 77.94 89.21 89.21 89.21
Announcement Date 05/12/19 03/12/20 02/12/21 08/12/22 07/12/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Oktober 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,653 2,431 2,922 3,308 3,593 3,886 4,149 4,415
EBITDA 1 886.2 719.9 930.9 948.9 1,218 1,150 1,258 1,364
EBIT 1 732.2 570 767.7 782.3 850.8 945.6 1,033 1,128
Operating Margin 27.59% 23.45% 26.27% 23.65% 23.68% 24.33% 24.89% 25.55%
Earnings before Tax (EBT) 1 477.4 266.5 491.5 475.3 412.9 558.3 729.7 857.9
Net income 1 466.7 238.4 2,945 385.8 294.2 452.3 601.4 708
Net margin 17.59% 9.81% 100.76% 11.66% 8.19% 11.64% 14.5% 16.03%
EPS 2 2.332 1.202 14.79 1.940 1.478 2.177 3.064 3.561
Free Cash Flow 1 421.1 176.2 524.2 450.4 215 324 599.8 725.6
FCF margin 15.87% 7.25% 17.94% 13.61% 5.98% 8.34% 14.46% 16.43%
FCF Conversion (EBITDA) 47.52% 24.48% 56.31% 47.47% 17.64% 28.17% 47.67% 53.21%
FCF Conversion (Net income) 90.23% 73.91% 17.8% 116.74% 73.08% 71.63% 99.73% 102.5%
Dividend per Share 2 0.0150 0.0150 0.0150 0.0150 0.0150 0.0600 0.0600 -
Announcement Date 05/12/19 03/12/20 02/12/21 08/12/22 07/12/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: October 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 787.2 829.8 843.4 848.1 858.5 877.4 930.2 927.1 931.6 942.6 997.5 1,011 991.5 1,010 1,063
EBITDA 1 233.5 245.5 238.8 231.2 237.4 254 317.1 319.2 - 323.1 291.8 303.9 306.4 305.2 -
EBIT 1 193.8 203.2 197.2 188.2 194.2 207.5 222.6 226.5 227.1 224.8 240.4 252.4 242.2 245.8 263.2
Operating Margin 24.62% 24.49% 23.38% 22.19% 22.62% 23.65% 23.93% 24.43% 24.38% 23.85% 24.1% 24.96% 24.43% 24.33% 24.77%
Earnings before Tax (EBT) 121.9 163.7 117.3 72.4 122.1 65.6 118.8 106.4 120 130 - - - - -
Net income 1 95.3 126.6 98.4 65.6 84.6 39.8 85.3 84.5 81.2 88.9 135.5 142.4 156.1 158.7 185.4
Net margin 12.11% 15.26% 11.67% 7.73% 9.85% 4.54% 9.17% 9.11% 8.72% 9.43% 13.58% 14.08% 15.74% 15.7% 17.44%
EPS 2 0.4775 0.6375 0.4950 0.3300 0.4250 0.2000 0.4275 0.4250 0.4100 0.4400 0.6629 0.7043 0.7533 0.7533 0.8533
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 03/03/22 02/06/22 31/08/22 08/12/22 02/03/23 01/06/23 30/08/23 07/12/23 29/02/24 30/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,737 1,677 1,383 2,625 2,450 2,277 1,761 1,204
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.96 x 2.33 x 1.486 x 2.767 x 2.011 x 1.98 x 1.4 x 0.8827 x
Free Cash Flow 1 421 176 524 450 215 324 600 726
ROE (net income / shareholders' equity) 13.5% 6.4% 12.2% 8.75% 8.66% 9.09% 9.43% 9.68%
ROA (Net income/ Total Assets) 7.54% 3.66% 8.06% 5.85% 5.51% 6.4% 6.8% 7%
Assets 1 6,194 6,506 36,521 6,593 5,338 7,067 8,845 10,114
Book Value Per Share 2 18.10 19.30 34.80 36.10 38.10 40.10 42.60 45.50
Cash Flow per Share 2 3.570 2.450 3.710 3.480 3.050 3.850 4.990 5.430
Capex 1 292 310 214 242 393 400 370 342
Capex / Sales 11.01% 12.77% 7.34% 7.31% 10.92% 10.3% 8.91% 7.74%
Announcement Date 05/12/19 03/12/20 02/12/21 08/12/22 07/12/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for The Cooper Companies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
89.21 USD
Average target price
109.7 USD
Spread / Average Target
+22.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Glasses, Spectacles & Contact Lenses

1st Jan change Capi.
ALCON INC. Stock Alcon Inc.
+23.25% 44.27B
AUTEK CHINA INC. Stock Autek China Inc.
-30.03% 1.93B
WARBY PARKER INC. Stock Warby Parker Inc.
+11.49% 1.87B
PEGAVISION CORPORATION Stock Pegavision Corporation
+22.32% 1.16B
SHANGHAI CONANT OPTICAL CO., LTD. Stock Shanghai Conant Optical Co., Ltd.
+73.94% 659M
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Stock Universal Vision Biotechnology Co., Ltd.
-12.09% 634M
MENICON CO., LTD. Stock Menicon Co., Ltd.
-44.04% 633M
MINGYUE OPTICAL LENS CO.,LTD. Stock Mingyue Optical Lens Co.,Ltd.
-48.16% 604M
VISCO VISION INC. Stock Visco Vision Inc.
+31.11% 551M
Glasses, Spectacles & Contact Lenses
  1. Stock Market
  2. Equities
  3. COO Stock
  4. CP60 Stock
  5. Financials The Cooper Companies, Inc.